Your search for oral corticosteroids returned 36 results

Four Phase 3 clinical trials of baricitinib in the treatment of moderate-to-severe active rheumatoid arthritis enrolled patients who were methotrexate-naïve or had inadequate response to methotrexate, conventional disease-modifying antirheumatic drugs (DMARDs) or DMARDs with TNF inhibitors.

Based on the pathophysiological and clinical characteristics of N-ERD, anti-IL 5 therapy may be effective in this patient subgroup.

Glucosamine sulfate is the only agent consistently effective on symptoms and joint structure changes in patients with knee osteoarthritis (OA).

Treatment with oral dexamethasone for 4 days significantly improved pain levels in the majority of outpatients with status migrainosus, a retrospective chart review presented at the 68th AAN Annual Meeting has found.

Exposure to glucocorticosteroids was associated with a significant increase in mortality, a finding that has “important implications for health care providers and people with arthritis,” results of a population-based cohort study reported at the 2013 ACR/ARHP Annual Meeting.

Treatment with single-agent carfilzomib achieved durable responses in patients with relapsed/refractory multiple myeloma whose disease had relapsed after they received all available therapies (including bortezomib and immunomodulatory agents), suggesting that this agent has the potential to offer substantial clinical benefit. The data was presented at the 52nd American Society of Hematology Annual Meeting and Exposition.